Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of higher-dose tigecycline versus imipenem/cilastatin for hospital-acquired pneumonia
2008-000412-33Phase 2Terminated
- Sponsor
- Wyeth
- Start
- May 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tigecycline and imipenem + cilastatin in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (3 arms), sponsored by Wyeth. Primary endpoint: Clinical response at test-of-cure in the clinically evaluable population. Started May 2008; status: terminated.
02
Drugs
tigecyclineimipenem + cilastatin
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2008-000412-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000412-33.